Editorial on Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers.
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue / Roviello G.; Generali D.; Ianza A.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - ELETTRONICO. - 11:(2019), pp. 365-368. [10.2217/imt-2018-0204]
Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: An evolving issue
Roviello G.
;
2019
Abstract
Editorial on Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
